Holen Sie sich die Stockscreener-App
12.52
3.22%
0.39
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$12.13
Offen:
$12.21
24-Stunden-Volumen:
52.86M
Relative Volume:
6.55
Marktkapitalisierung:
$14.94B
Einnahmen:
$15.05B
Nettoeinkommen (Verlust:
$-883.30M
KGV:
8.183
EPS:
1.53
Netto-Cashflow:
$1.89B
1W Leistung:
-0.87%
1M Leistung:
-4.65%
6M Leistung:
+22.03%
1J Leistung:
+19.81%
1-Tages-Spanne:
$12.14
$12.56
1-Wochen-Bereich:
$12.07
$12.78
52-Wochen-Spanne:
$9.925
$13.62
Viatris Inc Stock (VTRS) Company Profile
Firmenname
Viatris Inc
Sektor
Telefon
(724) 514-1465
Adresse
1000 MYLAN BOULEVARD, CANONSBURG
Vergleichen Sie VTRS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
12.52 | 14.94B | 15.05B | -883.30M | 1.89B | -0.74 |
|
ZTS
Zoetis Inc
|
164.84 | 74.37B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.69 | 43.81B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
22.09 | 25.03B | 16.77B | -959.00M | 1.37B | -0.85 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-19 | Fortgesetzt | Jefferies | Buy |
| 2023-10-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-06-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2023-04-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-02-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-10 | Hochstufung | UBS | Sell → Neutral |
| 2022-11-08 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | Fortgesetzt | Jefferies | Hold |
| 2022-06-14 | Eingeleitet | UBS | Sell |
| 2022-05-10 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | Eingeleitet | Citigroup | Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-03-08 | Herabstufung | Goldman | Buy → Neutral |
| 2021-03-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | Eingeleitet | Argus | Hold |
| 2020-12-14 | Eingeleitet | Bernstein | Mkt Perform |
Alle ansehen
Viatris Inc Aktie (VTRS) Neueste Nachrichten
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
What Makes Viatris (VTRS) a Favorite Stock for Billionaire David Einhorn? - Insider Monkey
Viatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology - The Malaysian Reserve
Cenerimod shows promise in SLE trial, Viatris reports - Investing.com
Viatris announces publication of CARE study results - TipRanks
Viatris's Lupus Drug Cenerimod Shows Powerful Disease Activity Improvement in Phase 2b Clinical Trial - StockTitan
(VTRS) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Lidocaine Patches Market to See Booming Growth 2024-2031 | Endo - openPR
Viatris's SWOT analysis: generic drug maker's stock faces growth hurdles - Investing.com
Viatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare Conference - The Eastern Progress Online
Epinephrine Autoinjector Market to Grow by USD 2.44 Billion (2024-2028), Driven by Rising Allergy Prevalence and AI-Powered Market TransformationTechnavio - The Malaysian Reserve
Viatris Announces the Pricing Terms of Pending Any and All Cash Tender Offers - The Eastern Progress Online
Catecholamines Drugs Market: Emerging Technology and Investor - openPR
Viatris Reports Third Quarter Financial Results for 2024 - Longview News-Journal
Viatris shareholders approve stock plan amendment, reject executive compensation By Investing.com - Investing.com Canada
Viatris shareholders approve stock plan amendment, reject executive compensation - Investing.com
(VTRS) Investment Analysis - Stock Traders Daily
Viatris Elects Directors and Amends Stock Plan at Meeting - Nasdaq
Generic Pharmaceuticals Market Future Business Opportunities - openPR
Coccidioidomycosis Drugs Market to Reach US$ 634.3 Million by 2034, Expanding at a CAGR of 4.9% | Fact.MR Report - GlobeNewswire Inc.
Anti Depression Drugs Market is expected to reach US$ 22.10 - openPR
Naloxone Market Growth in Future Scope 2024-2031 | Akorn, Inc, - openPR
Viatris Says Goodbye To Another Generics Asset - Citeline
2 Generic Drug Stocks Ready to Surge in 2025 - MarketBeat
Hypopituitarism Treatment Market to Witness Huge Growth - openPR
Hypovolemic Shock Market Growth Analysis: Industry Expansion - openPR
UK CMA fines Viatris for breaching order during Theramex deal probe - World Pharmaceutical Frontiers
Viatris fined in Morocco over merger notification, sources say - MSN
Vitaris fined in Morocco over merger notification, sources say - MSN
Morocco fines Viatris 7.58 million dirhams over Mylan-Pfizer merger - MSN
UK watchdog fines Viatris $1.9 mln over rule breach in Theramex probe - Reuters.com
Viatris Fined £1.5M For Failing To Comply With CMA Order - Law360
Viatris fined £1.5M for failure to comply with CMA order - MSN
Viatris fined £1.5M for failure to comply with CMA order (NASDAQ:VTRS) - Seeking Alpha
UK watchdog fines Viatris $1.9 million over rule breach in Theramex probe - Marketscreener.com
Viatris Fined £1.5M for CMA Order Breach - Mirage News
Viatris fined £1.5m for failure to comply with CMA order - GOV.UK
Ampicillin Market to Continue Impressive Measured Growth - openPR
Viatris Inc (VTRS)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus.com
Australia Passes Strict Social Media Ban for Under-16s - PYMNTS.com
Viatris fined in Morocco over merger notification, sources say By Reuters - Investing.com
Finanzdaten der Viatris Inc-Aktie (VTRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.34%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):